EP2300825A4 - P/gf-1 companion diagnostic methods and products - Google Patents

P/gf-1 companion diagnostic methods and products

Info

Publication number
EP2300825A4
EP2300825A4 EP09767690A EP09767690A EP2300825A4 EP 2300825 A4 EP2300825 A4 EP 2300825A4 EP 09767690 A EP09767690 A EP 09767690A EP 09767690 A EP09767690 A EP 09767690A EP 2300825 A4 EP2300825 A4 EP 2300825A4
Authority
EP
European Patent Office
Prior art keywords
products
diagnostic methods
companion diagnostic
companion
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09767690A
Other languages
German (de)
French (fr)
Other versions
EP2300825A1 (en
Inventor
Saul Datwyler
David J Hawksworth
Don M Laird
Dominick L Pucci
David C Sogin
Joan D Tyner
Robert N Ziemann
Richard R Lesniewski
Evelyn Mary Mckeegan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/485,114 external-priority patent/US8741287B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP2300825A1 publication Critical patent/EP2300825A1/en
Publication of EP2300825A4 publication Critical patent/EP2300825A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP09767690A 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products Withdrawn EP2300825A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7362408P 2008-06-18 2008-06-18
US8917208P 2008-08-15 2008-08-15
US11006308P 2008-10-31 2008-10-31
US12/485,114 US8741287B2 (en) 2008-06-18 2009-06-16 PlGF-1 assay and kits and components thereof
PCT/US2009/047714 WO2009155381A1 (en) 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products

Publications (2)

Publication Number Publication Date
EP2300825A1 EP2300825A1 (en) 2011-03-30
EP2300825A4 true EP2300825A4 (en) 2012-04-25

Family

ID=41434433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09767690A Withdrawn EP2300825A4 (en) 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products

Country Status (6)

Country Link
EP (1) EP2300825A4 (en)
JP (1) JP2011525241A (en)
CN (1) CN102224419A (en)
CA (1) CA2728449A1 (en)
MX (1) MX2010014228A (en)
WO (1) WO2009155381A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP2542096B1 (en) * 2010-03-05 2015-07-15 Ophthalmopharma AG Nutraceutical chocolate or compound chocolate product
SG10201806648TA (en) 2011-07-01 2018-09-27 Ngm Biopharmaceuticals Inc Compositions, uses and methods for treatment of metabolic disorders and diseases
UY34812A (en) * 2012-05-18 2013-12-31 Teva Pharma METHOD FOR TREATMENT OF LUNG CANCER OF NON-SMALL CELLS
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9963494B2 (en) 2012-11-28 2018-05-08 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
CN105008548B (en) 2012-12-27 2020-11-27 恩格姆生物制药公司 Methods for modulating bile acid homeostasis and treating bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
KR102652347B1 (en) * 2016-01-25 2024-03-27 사노피 Method for predicting outcome of treatment with aflibercept in patients suspected of having cancer by measurement of plasma biomarker levels
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2022099465A1 (en) * 2020-11-10 2022-05-19 宁波奥丞生物科技有限公司 Hybridoma cell strain 9c1, plgf-1 monoclonal antibody, preparation method therefor and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037224A1 (en) * 2005-08-11 2007-02-15 Hamer Peter J Quantitative assays for PDGFR-beta in body fluids
US20070254295A1 (en) * 2006-03-17 2007-11-01 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
DE102005022047A1 (en) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use
CN101534865A (en) * 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007056011A2 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2008030283A1 (en) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
MX2009004861A (en) * 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037224A1 (en) * 2005-08-11 2007-02-15 Hamer Peter J Quantitative assays for PDGFR-beta in body fluids
US20070254295A1 (en) * 2006-03-17 2007-11-01 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBERT D H ET AL: "Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 5, no. 4, 1 April 2006 (2006-04-01), pages 995 - 1006, XP002403181, ISSN: 1535-7163 *
CHIUNG-NIEN CHEN ET AL: "The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer", CANCER LETTERS, vol. 213, no. 1, 1 September 2004 (2004-09-01), pages 73 - 82, XP055020729, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2004.05.020 *
EBOS JOHN M L ET AL: "Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 43, 23 October 2007 (2007-10-23), pages 17069 - 17074, XP055020654, ISSN: 0027-8424 *
See also references of WO2009155381A1 *
SOO ET AL: "The effect of varying doses of ABT-869 on biomarkers of angiogensis and their correlation with pharmacodynamic outcome", no. Abst. 14535, May 2008 (2008-05-01), pages 1 - 2, XP002670638, Retrieved from the Internet <URL:http://tinyurl.com/847l6aq> [retrieved on 20120229] *

Also Published As

Publication number Publication date
EP2300825A1 (en) 2011-03-30
MX2010014228A (en) 2011-03-29
WO2009155381A1 (en) 2009-12-23
CN102224419A (en) 2011-10-19
JP2011525241A (en) 2011-09-15
CA2728449A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
EP2300825A4 (en) P/gf-1 companion diagnostic methods and products
HK1171792A1 (en) Diagnostic devices and related methods
GB0800144D0 (en) Electrocardiographic device and method
GB0813709D0 (en) Method and product
EP2419872A4 (en) Emotivity and vocality measurement
EP2299904A4 (en) Medical diagnostic devices and methods
EP2633278A4 (en) Photoacoustic sensor
ZA201104742B (en) Strains and methods for improving ruminant health and/or performance
GB0819720D0 (en) Methods and products
EP2578153A4 (en) Audiometer and method thereof
GB0921001D0 (en) Products and uses
GB0819883D0 (en) Product and uses
EP2545375A4 (en) Analyte sensor and associated methods
GB0918392D0 (en) Diagnostic and therapeutic methods
GB0821250D0 (en) Displacement measurement arrangement and method
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2569610A4 (en) Torque sensor assembly and method for producing same
PL2245463T3 (en) Diagnostic method
EP2350001A4 (en) Novel benzylidene-indolinone and their medical and diagnostic uses
GB0905076D0 (en) Diagnostic kits and methods
GB0814657D0 (en) Compsoitions and methods for maintaining lipid health
GB0903348D0 (en) Compounds and methods relating thereto
GB0802162D0 (en) Disposable products
GB0816772D0 (en) Medical product
GB0803731D0 (en) Methods and products

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PUCCI, DOMINICK, L.

Inventor name: MCKEEGAN, EVELYN, MARY

Inventor name: ZIEMANN, ROBERT, N.

Inventor name: TYNER, JOAN, D.

Inventor name: SOGIN, DAVID, C.

Inventor name: HAWKSWORTH, DAVID, J.

Inventor name: DATWYLER, SAUL

Inventor name: LAIRD, DON, M.

Inventor name: LESNIEWSKI, RICHARD, R.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/74 20060101ALI20120313BHEP

Ipc: G01N 33/574 20060101AFI20120313BHEP

Ipc: C07K 16/22 20060101ALI20120313BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120327

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101AFI20120320BHEP

Ipc: C07K 16/22 20060101ALI20120320BHEP

Ipc: G01N 33/74 20060101ALI20120320BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155804

Country of ref document: HK

17Q First examination report despatched

Effective date: 20121218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140226

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155804

Country of ref document: HK